HistoSonics, the manufacturer of the Edison® Histotripsy System, today announced that Highmark Blue Cross Blue Shield has ...

The global Liver Cancer Diagnostics Market is valued at USD 11.5 Billion in 2024 and is projected to reach a value of USD ...

In order to produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic ...

The Foundation also awarded Continuation Grants to three Damon Runyon Clinical Investigators, totaling $1,000,000 in additional funding. The Continuation Grants are designed to support Clinical ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

Patients with liver diseases will have expanded access to advanced ultrasound imaging and transplant options, thanks to new policy allowing doctors to use contrast-enhanced ultrasound (CEUS) to help ...

Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development ...

The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in a ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

It started with a candy cane. A small gesture. A shy smile. A moment of unexpected kindness between two boys whose paths might never have crossed – if not for the one thing no children should ever ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ...